IL-BAI
28.1.2021 14:32:08 CET | Business Wire | Press release
BAI announced the finalists for the 2020 BAI Global Innovation Awards , the industry’s prestigious awards program that celebrates new and innovative solutions in the financial services industry worldwide.
Now in its tenth year, the BAI Global Innovation Awards recognizes leading financial services organizations on a global scale. This year, the awards drew hundreds of nominations from industry leaders demonstrating how their organizations used innovation to tackle their challenges in creative, impactful ways. Each nomination is evaluated by the Innovation Circle , a panel of global financial services innovation leaders who weigh each submission on originality and impact on consumers, employees, communities and the industry to determine the top innovations of the year.
The 2020 BAI Global Innovation Awards finalists are:
Consumer Products of Services Innovation
- Bank Pekao S.A., Poland: PeoPay KIDS
- CaixaBank S.A., Spain: HolaBank – Onboarding + mortgageNow
- FNB Life, South Africa: Dynamic Life – Home
- Meridian Credit Union, Canada: Meridian’s Price Drop
- OneConnect Smart Technology Co., Ltd. (Shenzhen), China: Smart Fast Claim
Customer Experience Innovation
- Bank of Montreal, Canada: BMO AI Cashflow Prediction
- Commonwealth Bank of Australia: Bill Sense
- DBS Bank Ltd, Singapore: DBS Chatbot – Guided Conversation
- Finicity, United States: Empowering the Customer Through Open Banking & Credit Decisioning
- FNB Life, South Africa: We’ve Got You COVI(R)D
Human Capital Innovation
- Citizens Financial Group, United States: Jamie Virtual Career Assistant
- SberBank, Russia: Employee Digital Care Program
- Ziraat Bank, Turkey: Hidden Power of Communication
Internal Process Innovation
- CaixaBank S.A., Spain: The New Mobility Section at Now
- DenizBank, Turkey: Digital Scorecard
- ICICI Bank, India: OPTIMUS – Payment Invoicing and ID Card Issuance System
- OneConnect Smart Technology Co., Ltd. (ShenZhen), China: Smart Contract Cloud Platform
- SberBank, Russia: Contact Center Internal Improvement Process
Marketing Innovation
- Emirates NBD Bank, United Arab Emirates: Emirates NBD Anti-Phishing "It Wasn't Me" Campaign
- imaginTech S.A., Spain: New imagin, a New Way to Communicate
- Synchrony, United States: Millie: A Multi-Channel Personal Finance Platform for Women
RegTech Innovation
- Abu Dhabi Global Market Financial Center (ADGM), United Arab Emirates: ADGM and ClauseMatch collaborate to launch Regulation 2.0
- Fino Payments Bank, India: Enterprise Risk & Fraud Management solution
- KAL ATM Software, Germany: New approach to costly and disruptive ATM hardware upgrades
- Ping An Technology (Shenzhen) Co., Ltd., China: Pingan Beehive Federated Intelligence Platform
Small Business Products or Services Innovation
- Aliasware, Inc., United States: PayVus Small Business Credit Card
- Banco Bradesco, Brazil: Open Banking Initiative: Portal MEI, Solutions for the Individual Micro Entrepreneur
- İşbank, Turkey: TekCap
- RBC Ventures, Canada: Ownr
Societal and Community Impact Innovation
- Citi Ventures Studio, United States: City Builder
- Union Bank of the Philippines: UBX SeekCap
- Woodforest National Bank, United States: Woodforest CEI-Boulos Opportunity Fund
Congratulations to all the finalists of the 2020 BAI Global Innovation Awards. The winners will be announced in February. To learn more please visit BAI Global Innovation Awards .
About BAI
As a nonprofit, independent organization, BAI has delivered the financial services industry’s most actionable insights for more than 95 years, enabling leaders to make smart business decisions every day. We provide in-depth, proprietary research to more than 40 of the top US banks, support more than 2,100 financial services organizations with compliance and professional development training, provide trusted, relevant thought leadership through BAI Banking Strategies reports, podcasts and webinars, and offer specialized events and programs. For more information, visit www.bai.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210128005646/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom